PolyPid (PYPD) to Release Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

PolyPid Stock Up 0.3 %

PolyPid stock opened at $3.07 on Tuesday. PolyPid has a one year low of $2.37 and a one year high of $7.00. The stock’s 50 day moving average price is $3.03 and its 200 day moving average price is $3.33. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00.

Wall Street Analysts Forecast Growth

PYPD has been the subject of several analyst reports. Rodman & Renshaw initiated coverage on shares of PolyPid in a research note on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price for the company. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Craig Hallum began coverage on PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright lowered their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.